Latis

Latis Bio is a clinical-stage biotechnology company focused on developing microbiome-based therapies for inflammatory skin diseases. The company's lead program, LB-001, is a live biotherapeutic product containing a specific strain of Roseomonas mucosa, which is being evaluated for the treatment of atopic dermatitis in both adults and children. Latis Bio's approach centers on restoring the natural balance of the skin's ecosystem to suppress the growth of pathogenic bacteria like Staphylococcus aureus. Founded on research from the National Institute of Allergy and Infectious Diseases (NIAID), the company aims to provide a non-steroidal, safe alternative for chronic skin conditions. The company is backed by prominent venture capital firms and is currently advancing its clinical pipeline through Phase 2 trials.